IJMPR 2025, 9(1), 33-37

International Journal of Modern Pharmaceutical Research
www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Review Article
SJIF Impact Factor: 6.669

A REVIEW ON ANTIMICROBIAL RESISTANCE: CHALLENGES AND FUTURE PROSPECTS

P. Akhila[*1], K. Vedith Reddy[1], S. Veena[1], K. Harshitha[1] and Dr. K. T. Naik[2]

[1]Pharm. D. Interns, Krishna Teja Pharmacy College, Tirupathi, Andra Pradesh.
[2]Associate Professor, Krishna Teja Pharmacy College, Tirupathi, Andra Pradesh.

Article Received on: 11/11/2024
Article Revised on: 01/12/2024
Article Accepted on: 21/12/2024

***Corresponding Author**
P. Akhila
Pharm. D. Interns, Krishna Teja Pharmacy College, Tirupathi, Andra Pradesh.

ABSTRACT

Antimicrobial resistance (AMR) is a pressing global health crisis fueled by the misuse and overuse of antibiotics across healthcare, agriculture, and animal husbandry. Since the discovery of penicillin, the rise of multidrug-resistant pathogens has posed severe challenges to healthcare systems worldwide. Mismanagement of antibiotics in human and veterinary medicine, along with agricultural practices, accelerates the spread of resistance genes, creating a "Silent Pandemic" predicted to surpass other leading causes of mortality by 2050. Emerging technologies, including artificial intelligence, offer promising tools to combat AMR by enhancing diagnostics and optimizing treatment strategies. However, challenges such as data quality and algorithmic biases must be addressed to fully realize their potential. Key strategies include strengthening surveillance systems, implementing antimicrobial stewardship programs, and investing in the research and development of novel antimicrobials. Raising public awareness, improving education, and fostering international collaboration are vital to preserving the efficacy of antibiotics and safeguarding public health for future generations. Addressing AMR requires urgent, coordinated efforts to mitigate its escalating threat and ensure sustainable global health outcomes. This review highlights the urgent need for equitable access to resources, enhanced global collaboration, and sustained investments to mitigate the AMR crisis. By implementing these strategies, the global community can safeguard the effectiveness of antimicrobials and protect public health against the escalating threat of resistant infections.

KEYWORDS: Antimicrobial resistance, Preventive strategies, Stewardship, Global action plan, Center for disease control and prevention.

Antimicrobial resistance: Antimicrobial resistance (AMR) refers to the phenomenon where microorganisms (such as bacteria, fungi, viruses, and parasites) evolve and develop the ability to resist the effects of drugs that were previously effective in treating infections caused by them. In simpler terms, AMR means that the microorganisms are able to survive and even multiply despite the presence of antimicrobial agents (like antibiotics, antifungals, or antivirals) that would normally kill or inhibit their growth. This resistance can occur naturally over time, but it is often accelerated by factors such as overuse or misuse of antimicrobial drugs in healthcare, agriculture, and other settings.[1,2]

AMR - History: The history of antimicrobial resistance (AMR) is deeply intertwined with the discovery and widespread use of antibiotics, starting with penicillin. When Alexander Fleming discovered penicillin in 1928, it revolutionized medicine and led to the mass production of antibiotics in the 1940s. This new class of drugs saved countless lives by treating bacterial infections that had previously been fatal. However, it didn't take long for bacteria to begin developing resistance to penicillin. The first cases of penicillin-resistant *Staphylococcus aureus* were reported in 1942, only a few years after penicillin's introduction. Resistance to other antibiotics, such as tetracycline, soon followed by the early 1950s. In the 1950s and 1960s, the agricultural use of antibiotics to promote growth in livestock further accelerated the development and spread of resistant bacteria. As bacteria became more resistant, the emergence of multi-drug resistant (MDR) strains became a growing concern. One of the most notable early examples was the appearance of methicillin-resistant *Staphylococcus aureus* (MRSA) in 1961, which was followed by resistance to multiple antibiotic classes over the following decades. The 1980s brought a global epidemic of multidrug-resistant tuberculosis (MDR-TB), highlighting the severity of AMR on a global scale. In the 1990s, resistance spread among Gram-negative pathogens like *Escherichia coli* and *Klebsiella pneumoniae*, which developed resistance to extended-spectrum beta-lactamases (ESBLs), further limiting treatment options for serious infections.[3,4]

The rise of multidrug resistance (MDR) has led to a reduction in the number of effective antibiotics available to treat infections. The lack of new antibiotics and the growing resistance of existing ones have significantly strained healthcare systems worldwide. Today, we find ourselves in what is increasingly referred to as the **post-antibiotic era**, where common infections and even minor injuries, which were once easily treatable with antibiotics, could become life-threatening again. If the current trends continue and no urgent solutions are implemented, the World Health Organization (WHO) has warned that AMR could result in millions of deaths annually, with infections becoming harder and harder to treat. Addressing AMR requires a multifaceted approach: improved stewardship of existing antibiotics, a commitment to developing new drugs and diagnostics, changes in agricultural antibiotic use, and global cooperation to combat the spread of resistant pathogens. The future of public health may depend on how effectively we can respond to the growing threat of AMR.[3,5]

MECHANISM OF AMR

1. **Enzymatic Modification or Degradation**: Many bacteria produce enzymes that can degrade or modify antibiotics, rendering them ineffective. For example, **beta-lactamases** break down the beta-lactam ring of penicillins and cephalosporins, while other enzymes modify aminoglycosides or macrolides, preventing them from binding to their targets.
2. **Limiting Antibiotic Entry**: Some bacteria can reduce the influx of antibiotics into their cells. This can occur through **altered porin channels**, which are responsible for the transport of molecules into the cell. Mutations in these channels can limit the amount of antibiotic that enters, thereby reducing its effectiveness. For instance, **Pseudomonas aeruginosa** often reduces the expression of porins to block antibiotics like carbapenems.
3. **Alterations to Metabolic Pathways**: Bacteria can develop resistance by bypassing the metabolic pathways targeted by antibiotics. For example, sulfonamides inhibit the synthesis of folic acid, but some bacteria can acquire or develop alternative pathways to produce folic acid without the need for the enzyme targeted by the drug.
4. **Modification of Target Sites**: Bacteria may alter the structures of their cellular targets (such as ribosomes, cell wall components, or enzymes) so that antibiotics can no longer bind effectively. For example, **MRSA** (methicillin-resistant *Staphylococcus aureus*) alters its penicillin-binding protein (PBP) to avoid binding to beta-lactam antibiotics like methicillin.
5. **Efflux Pumps**: Efflux pumps are specialized transporters that actively expel antibiotics out of the bacterial cell before they can reach therapeutic concentrations. These pumps can be specific for one type of antibiotic, or they can be multidrug-resistant (MDR) pumps that eject several types of antibiotics, making bacteria resistant to a range of drugs.
6. **Biofilm Formation**: Some bacteria can form **biofilms**, which are structured communities of bacteria embedded in a protective extracellular matrix. Biofilms can develop on medical devices (e.g., catheters, prosthetics) or in tissues and are known to be highly resistant to both antibiotics and the host immune system. The biofilm provides a physical barrier to antibiotics and creates areas of reduced nutrient availability, which can make bacteria in biofilms less susceptible to treatment.[3,6,7]



Fig 1: Mechanism of AMR in Bacteria.

Horizontal Gene Transfer and Spread of Resistance: Bacteria are also adept at acquiring resistance genes from other bacteria, often through **horizontal gene transfer (HGT)**. This can happen through.

1. **Conjugation**: The transfer of genetic material between bacteria through direct cell-to-cell contact. This is often mediated by plasmids, small DNA molecules that can carry multiple resistance genes. For example, plasmids carrying **beta-lactamase genes** can confer resistance to multiple beta-lactam antibiotics.
2. **Transformation**: Some bacteria can take up naked DNA from their environment, including DNA from dead bacteria that may carry resistance genes.
3. **Transduction**: **Bacteriophages** (viruses that infect bacteria) can transfer DNA between bacterial cells. This can spread resistance genes quickly across bacterial populations.[3,8]

OBJECTIVES OF AMR-GAP

1. Improve Awareness and Understanding of AMR; Objective: Raise awareness about the dangers of AMR and improve understanding among the general public, healthcare professionals, and policymakers.

2. Strengthen Governance and Accountability; Objective: Strengthen national and global leadership, coordination, and governance of AMR initiatives.

3. Optimize the Use of Antimicrobials; Objective: Ensure that antimicrobials are used responsibly in human and animal health, as well as in agriculture.

4. Enhance Infection Prevention and Control (IPC) Measures; Objective: Improve infection prevention and control (IPC) measures in both healthcare settings and the community to reduce the spread of resistant pathogens.

5. Foster Innovation and Investment in AMR Solutions; Objective: Stimulate the development of new antibiotics, vaccines, diagnostics, and other tools to address AMR, and promote equitable access to these innovations.[8,9]



Fig 2: Five objectives of global action plan of AMR.

Key Challenges of AMR

1. **Widespread Utilization and Overdependence on Antimicrobials:** Antimicrobial are deeply embedded in healthcare, agriculture, and food production systems. Empiric antibiotic prescribing persists in clinical settings due to the absence of rapid, accessible diagnostic tools.
2. **Agricultural Contributions to Resistance:** Regular use of antibiotics in animal husbandry for prophylaxis and growth promotion exacerbates resistance. Policy inertia and economic reliance on current practices impede progress in sustainable livestock management.
3. **Antibiotic Development Pipeline Constraints:** The lack of financial incentives has led many pharmaceutical companies to abandon antimicrobial research. Long timelines for drug trials and regulatory approval further delay the introduction of new antibiotics.
4. **Fragmented Global Response:** AMR surveillance and stewardship efforts are inconsistent across countries, creating gaps in global containment. Peak enforcement of guidelines and inequitable access to diagnostics undermine progress.
5. **Economic Burden:** Resistant infections impose significant costs due to prolonged hospital stays, advanced treatment requirements, and societal productivity losses. Healthcare systems in low- and middle-income countries often lack resources to manage the economic and health impacts effectively.
6. **Increased treatment failure:** Resistant pathogens (e.g., staphylococcus aureus or pseudomonas

aeruginosa) make it challenging to treat common infections Second line or combination therapies often have greater side effects, are costlier, and may require longer durations.

7. **Limited treatment options:** Overuse and misuse of antibiotics contribute to resistance, reducing the efficacy of frontline antimicrobials.[10,11,12]

FUTURE PROSPECTS OF AMR

1. **Strengthening Antimicrobial Stewardship (AMS) Programs**

- Implement mandatory AMS policies across all healthcare settings, focusing on reducing unnecessary prescriptions.
- Expand AMS into veterinary and agricultural sectors with clear metrics and oversight mechanisms.

2. **Advancing Diagnostic Technologies**

- Invest in the development and deployment of affordable, rapid point-of-care diagnostics.
- Integrate diagnostic tools into healthcare systems, especially in resource-limited settings, to minimize empiric prescribing.

3. **Revitalizing Antibiotic Development**

- Establish global incentives (e.g., market entry rewards, subsidies, public-private partnerships) to encourage antibiotic research.
- Support alternative approaches such as bacteriophage therapy, immunotherapy, and biofilm disruptors.

4. **Enhancing International Collaboration**

- Strengthen organizations like the WHO, CDC, and UN to enforce binding international agreements on AMR containment.
- Share AMR surveillance data and best practices to create a unified global database.

5. **Reforming Agricultural Practices**

- Transition toward sustainable farming systems that minimize reliance on antibiotics.
- Provide subsidies or incentives for adopting alternatives, such as vaccines for livestock or probiotics.

6. **Education and Advocacy**

- Raise awareness about AMR among healthcare providers, veterinarians, policymakers, and the public.
- Encourage behavioural change campaigns promoting judicious antibiotic use.

7. **Economic Support for Affected Nations**

- Allocate international funding to help low- and middle-income countries strengthen health infrastructure and diagnostic access.
- Collaborate with global financial institutions to offset the costs of implementing robust AMS policies.[3,10&13]

CONCLUSION

Antimicrobial resistance (AMR) represents one of the most pressing global health challenges, threatening the foundation of modern medicine. The growing prevalence of multidrug-resistant pathogens underscores the urgency of addressing this crisis comprehensively. AMR is driven by the widespread misuse and overuse of antibiotics across human healthcare, agriculture, and veterinary sectors, coupled with insufficient innovation in diagnostic tools and therapeutic options. While challenges remain formidable, future prospects for combating AMR are promising with concerted global efforts. Implementing robust antimicrobial stewardship programs, advancing rapid diagnostic technologies, and revitalizing antibiotic development pipelines are critical steps. Addressing AMR also demands international collaboration through a One Health approach, recognizing the interconnectedness of human, animal, and environmental health.[14]

Ultimately, overcoming AMR will require equitable access to resources, sustained investment in research, and binding global policies to curb resistance and promote innovation. Failure to act decisively risks a post-antibiotic era where routine medical procedures become perilous and infectious diseases reclaim dominance as leading causes of mortality. By prioritizing collective action and innovation, humanity can preserve the efficacy of antimicrobial therapies and safeguard future generations. A significant strategy must be made in conjunction with determined efforts in the direction of infection prevention, better antibiotic use, and stopping the spread of resistance when it does arise (Centers for Disease Control and Prevention, 2019).[5,15]

REFERENCES

1. Moh Aijaz et al, antimicrobial resistance in a globalized world: current challenges and future perspectives, international journal of pharmaceutical drug design, 1(1):7-22.
2. Acar, J.; Epizooties, B.R.T.-O.I. des; 2001, undefined Antimicrobial Resistance: An Overview. researchgate.net, doi:10.20506/rst.20.3.1309.
3. Sirwan khalid ahmed et al, antimicrobial resistance: impacts, challenges, and future prospects, journal of medicine, surgery, and public health, 1 march 2024.
4. Bipin puri et al, antimicrobial resistance: current challenges and future directions, medical journal armed forces india, 19 september 2024.
5. Shikha sharma et al, emerging challenges in antimicrobial resistance: implications for pathogenic microorganisms, novel antibiotics, and their impact on sustainability, pub med., 2024 Apr 29; 15.
6. H. Mohanty, S. Pachpute, R. P. Yadav Mechanism of drug resistance in bacteria: efflux pump modulation for designing of new antibiotic enhancers Folia Micro boil., 2021; 66: 727-739.
7. C. Uruén, G. Chopo-Escuin, J. Tommassen, R.C. Mainar-Jaime, J. Arenas Biofilms as promoters of bacterial antibiotic resistance and tolerance Antibiotics, 2021; 10(1): 36.
8. Drug resistance infections final report, a threat to our economic future, march 2017.

9. Rajesh Bhatia et al, universal health coverage framework to combat antimicrobial resistance, the Indian journal of medical research, March 2018; 147(3): 228.
10. Sirwan Khalid Ahmed et al, antimicrobial resistance: Impacts, challenges, and future prospects, journal of medicine surgery and public health, 2 Apr. 2024.
11. M.M. Rahman et al, An Overview of Antimicrobial Stewardship Optimization: The Use of Antibiotics in Humans and Animals to Prevent Resistance, Antibiotics, 2022; 11: 667.
12. G.M. Du Plessis, Microbial Geopolitics: Living with Danger and the Future of Security., Ph.D. diss., (2017).
13. Valentina Straniero et al, Finding ways to fight antimicrobial resistance: present, future, and perspectives, february 2024; 13(2): 6.
14. David chinemerem nwobobo et al, antibiotic resistance: the challenge and some emerging strategies for tackling a global menace, journal of clinical laboratory analysis, 2022 august 10; 36(9).
15. Sen pei et al, challenges in forecasting antimicrobial resistance, centre for disease control and prevention, april 2023; 29(4).